{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:19:28Z","timestamp":1792088368309,"version":"4.4.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.jaci.2004.04.046","type":"journal-article","created":{"date-parts":[[2004,7,6]],"date-time":"2004-07-06T11:17:14Z","timestamp":1089112634000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["The biology of Kit in disease and the application of pharmacogenetics"],"prefix":"10.1016","volume":"114","author":[{"family":"Cem Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2004.04.046_BIB1","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand","volume":"6","author":"Yarden","year":"1987","journal-title":"EMBO J"},{"key":"10.1016\/j.jaci.2004.04.046_BIB2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/320415a0","article-title":"A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family","volume":"320","author":"Besmer","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2004.04.046_BIB3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.1460-2075.1988.tb02907.x","article-title":"Primary structure of c-kit: relationship with the CSF-1\/PDGF receptor kinase family\u2013oncogenic activation of v-kit involves deletion of extracellular domain and C terminus","volume":"7","author":"Qiu","year":"1988","journal-title":"EMBO J"},{"key":"10.1016\/j.jaci.2004.04.046_BIB4","first-page":"369","article-title":"Oncogenic activation of v-kit involves deletion of a putative tyrosine- substrate interaction site","volume":"10","author":"Herbst","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.jaci.2004.04.046_BIB5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00291740","article-title":"Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4","volume":"78","author":"d'Auriol","year":"1988","journal-title":"Hum Genet"},{"key":"10.1016\/j.jaci.2004.04.046_BIB6","first-page":"965","article-title":"The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others","volume":"142","author":"Galli","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","article-title":"The role of Kit-ligand in melanocyte development and epidermal homeostasis","volume":"16","author":"Wehrle-Haller","year":"2003","journal-title":"Pigment Cell Res"},{"issue":"suppl","key":"10.1016\/j.jaci.2004.04.046_BIB8","doi-asserted-by":"crossref","first-page":"137S","DOI":"10.1038\/jid.1994.25","article-title":"Molecular basis of human piebaldism","volume":"103","author":"Spritz","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1300","article-title":"Apoptosis and melanoma: molecular mechanisms","volume":"199","author":"Hussein","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/ror.0.0050143","article-title":"Roles of KIT and KIT LIGAND in ovarian function","volume":"5","author":"Driancourt","year":"2000","journal-title":"Rev Reprod"},{"key":"10.1016\/j.jaci.2004.04.046_BIB11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1439-0272.2003.00539.x","article-title":"Molecular mechanisms utilized by alternative c-kit gene products in the control of spermatogonial proliferation and sperm-mediated egg activation","volume":"35","author":"Rossi","year":"2003","journal-title":"Andrologia"},{"key":"10.1016\/j.jaci.2004.04.046_BIB12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood.V78.7.1706.1706","article-title":"Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule","volume":"78","author":"Okada","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.148.3.772","article-title":"Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells","volume":"148","author":"Kirshenbaum","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB16","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1084\/jem.183.6.2681","article-title":"Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo","volume":"183","author":"Costa","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011083031272","article-title":"Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL","volume":"21","author":"Mekori","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(88)90020-7","article-title":"The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene","volume":"55","author":"Geissler","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2004.04.046_BIB20","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood.V78.8.1942.1942","article-title":"Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene","volume":"78","author":"Tsujimura","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0014-4827(92)90189-F","article-title":"The ret oncogene can induce melanogenesis and melanocyte development in Wv\/Wv mice","volume":"200","author":"Iwamoto","year":"1992","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/0008-5472.CAN-03-2532","article-title":"c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model","volume":"64","author":"Kato","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB23","first-page":"939","article-title":"Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression","volume":"10","author":"Montone","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00008390-199602000-00004","article-title":"c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi","volume":"6","author":"Ohashi","year":"1996","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C","article-title":"Molecular mechanisms of melanoma metastasis","volume":"173","author":"Bar-Eli","year":"1997","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB26","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1016\/S0021-9258(18)53623-1","article-title":"Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor","volume":"268","author":"Blechman","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2004.04.046_BIB27","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1074\/jbc.272.10.6311","article-title":"Kit receptor dimerization is driven by bivalent binding of stem cell factor","volume":"272","author":"Lemmon","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2004.04.046_BIB28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0092-8674(95)90455-7","article-title":"The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction","volume":"80","author":"Blechman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2004.04.046_BIB29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","article-title":"Early signaling pathways activated by c-Kit in hematopoietic cells","volume":"31","author":"Linnekin","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB30","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/sj.onc.1205317","article-title":"Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease","volume":"21","author":"Scheijen","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jaci.2004.04.046_BIB31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2141.1995.tb05364.x","article-title":"c-kit point mutation of extracellular domain in patients with myeloproliferative disorders","volume":"91","author":"Nakata","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2141.2003.04108.x","article-title":"Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis","volume":"120","author":"Abu-Duhier","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia","volume":"105","author":"Gari","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","article-title":"C-kit mutations in core binding factor leukemias","volume":"95","author":"Beghini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","article-title":"KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors","volume":"156","author":"Lux","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0002-9440(10)64623-8","article-title":"Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases","volume":"157","author":"Lasota","year":"2000","journal-title":"Am J Pathol"},{"issue":"suppl","key":"10.1016\/j.jaci.2004.04.046_BIB37","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0959-8049(02)80602-5","article-title":"Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review","volume":"38","author":"Miettinen","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaci.2004.04.046_BIB38","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaci.2004.04.046_BIB41","first-page":"2345","article-title":"Specific c-kit mutations in sinonasal natural killer\/T-cell lymphoma in China and Japan","volume":"60","author":"Hongyo","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB42","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/gast.2001.20880","article-title":"Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene","volume":"120","author":"Maeyama","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2004.04.046_BIB44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D","article-title":"Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa","volume":"92","author":"Beghini","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2004.04.046_BIB45","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-03-0110","article-title":"Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia","volume":"10","author":"Robson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB46","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1073\/pnas.1037763100","article-title":"Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase","volume":"100","author":"Sommer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2004.04.046_BIB47","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2004.04.046_BIB48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2004.04.046_BIB49","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0002-9440(10)65419-3","article-title":"Activating c-kit gene mutations in human germ cell tumors","volume":"154","author":"Tian","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB51","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0145-2126(03)00093-6","article-title":"Multilineage hematopoietic involvement in systemic mastocytosis","volume":"27","author":"Akin","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V88.3.995.995","article-title":"Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase","volume":"88","author":"Kitayama","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB55","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2004.04.046_BIB56","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C","article-title":"Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis","volume":"83","author":"Worobec","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2004.04.046_BIB57","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/shem.2003.50037","article-title":"Imatinib: a targeted clinical drug development","volume":"40","author":"Capdeville","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB60","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2004.04.046_BIB62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB63","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB64","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jaci.2004.04.046_BIB65","first-page":"3231a","article-title":"Effects of the tyrosine-kinase inhibitor STI571 on mutated KIT and neoplastic mast cells","volume":"96","author":"Akin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB66","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jaci.2004.04.046_BIB67","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB68","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2004.04.046_BIB69","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2004.04.046_BIB70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB71","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2004.04.046_BIB72","first-page":"722","article-title":"Hypopigmentation in an African patient treated with imatinib mesylate: a case report","volume":"95","author":"Hasan","year":"2003","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jaci.2004.04.046_BIB73","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2004.04.046_BIB74","first-page":"5353","article-title":"Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251","volume":"52","author":"Andrejauskas-Buchdunger","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB75","first-page":"17","article-title":"PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.jaci.2004.04.046_BIB76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaci.2004.04.046_BIB77","first-page":"3420a","article-title":"PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation [abstract]","volume":"102","author":"Gotlib","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin","volume":"42","author":"Schulte","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaci.2004.04.046_BIB79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/0929867033457818","article-title":"Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification","volume":"10","author":"Neckers","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaci.2004.04.046_BIB80","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2004.04.046_BIB81","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2004.04.046_BIB82","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674904014174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674904014174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:51:48Z","timestamp":1758775908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674904014174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0091674904014174"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2004.04.046","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biology of Kit in disease and the application of pharmacogenetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2004.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Allergy, Asthma and Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}